Biogen Inc.
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedr…
What to know about BIIB
Biogen Inc. is a large Healthcare company with a mixed financial profile. It scores well on cash flow and risk, but growth is worth keeping an eye on.
Should you consider BIIB?
Based on 31 financial metrics and sector comparison. Not financial advice.
-
Biogen Inc. is a large-cap Healthcare company with a mixed overall financial profile — it ranks in the top quarter of its Healthcare peers (15 of 59).
-
Profitability is roughly average for the S&P 500 — not a standout in either direction.
-
Valuation is in the middle of the pack — neither obviously cheap nor stretched.
-
Growth has been slower than most peers. That's not necessarily a dealbreaker, but it means the investment case rests more on current earnings than future expansion.
-
This stock pays no dividend — your return depends entirely on the share price rising over time.
-
Risk is relatively low — the stock tends to be less volatile than the broader market, which typically means a smoother ride during uncertain periods.
-
This is a mixed picture — real strengths in some areas, but areas that need watching too. Do your homework on the sector before deciding.
At a glance
How it scores
We look at 31 different financial metrics and group them into categories. Here's how BIIB compares to the other S&P 500 stocks.
Dive deeper — all 31 metrics 9 categories · valuation, growth, health, dividends & more Show all Hide
Valuation
Is the stock cheap or expensive relative to its earnings, sales, and assets? Lower multiples often mean better value.
| Metric | Value | vs S&P 500 |
|---|---|---|
| P/E Ratio (Trailing) | 21.16 | Above avg |
| Forward P/E | 11.78 | Top 25% |
| PEG Ratio | 3.94 | Below avg |
| Price to Sales | 2.92 | Above avg |
| Price to Book | 1.56 | Top 25% |
| EV/EBITDA | 8.80 | Top 25% |
| Earnings Yield | 4.73% | Above avg |
Profitability
How efficiently does the company turn revenue into profit? Higher margins mean more money kept from each dollar earned.
| Metric | Value | vs S&P 500 |
|---|---|---|
| Gross Margin | 78.72% | Top 25% |
| Operating Margin | 22.90% | Above avg |
| Net Profit Margin | 13.80% | Above avg |
| Return on Equity | 7.70% | Below avg |
| Return on Invested Capital | 5.95% | Above avg |
Growth
How fast is the business expanding? Strong growth in revenue and earnings signals increasing market demand.
| Metric | Value | vs S&P 500 |
|---|---|---|
| Revenue Growth (YoY) | 1.90% | Below avg |
| Revenue Growth (3Y CAGR) | -0.94% | Below avg |
| EPS Growth (YoY) | 31.10% | Above avg |
| Free Cash Flow Growth | -21.72% | Below avg |
Health
Can the company cover its debts and obligations? A healthy balance sheet reduces the risk of financial trouble.
| Metric | Value | vs S&P 500 |
|---|---|---|
| Current Ratio | 3.06 | Top 25% |
| Debt to Equity | 0.35 | Top 25% |
| Interest Coverage | 6.82 | Average |
| Altman Z-Score | 3.30 | Above avg |
Dividends
Does the company pay shareholders, and is that payment growing and sustainable?
| Metric | Value | vs S&P 500 |
|---|---|---|
| Dividend Yield | — | N/A |
| Payout Ratio | 0.00% | Top 25% |
| Dividend Growth (5Y) | — | N/A |
Cash Flow
Is real cash flowing into the business — not just accounting profits? Strong cash flow funds growth and dividends.
| Metric | Value | vs S&P 500 |
|---|---|---|
| Free Cash Flow Yield | 7.98% | Top 25% |
| OCF to Sales | 26.07% | Above avg |
Risk
How volatile is the stock compared to the broader market? Lower beta and volatility mean a smoother ride.
| Metric | Value | vs S&P 500 |
|---|---|---|
| Beta (1-Year) | 0.18 | Top 25% |
| Volatility (30-Day) | 32.88% | Average |
Sentiment
What do analysts and short-sellers think? High analyst ratings and low short interest signal broad confidence.
| Metric | Value | vs S&P 500 |
|---|---|---|
| Short % of Float | 3.60% | Average |
| Avg. Analyst Rating | 1.97 | Above avg |
| Target Upside % | 11.98% | Average |
Size
How large is the company by market value? Size affects stability, growth potential, and index inclusion.
| Metric | Value | vs S&P 500 |
|---|---|---|
| Market Capitalization | 29.02B | Average |
How does BIIB compare to…?
Pick another stock and see them side by side in seconds.
You might also look at
Companies in a similar position to BIIB — based on their financial profile.